



[Workers' Comp](#)

North Carolina Utilization Rules for Opioid and Other Pharmacological Pain Management Treatment

June 19, 2018
2 MIN READ

When do the new rules apply?

The rules apply to all affected treatments in all affected claims on or after **May 1, 2018**.

Affected claims: Any NC claim unless the patient has been receiving a “*targeted controlled substance*” for **more than 12 consecutive weeks immediately prior to 5/1/18**.

Affected treatment: Pain management treatment for non-cancer pain in WC claims.

Exception: medications administered in a health care setting.

What’s in the new rules?

Controlled Substance Reporting System (CSRS) mandate – Effective Nov. 1, 2018

- Requires prescribers to check CSRS at certain points in treatment.

Clinical guidelines and preauthorization requirements – Effective May 1, 2018

- Different guidelines for:
 - 1st prescription in “*acute phase*”
 - Subsequent prescriptions in “*acute phase*”
 - Prescriptions in “*chronic phase*”
- Requirement to “consider” prescribing an opioid antagonist in certain scenarios.
- Suggestions to “consider” non-pharmacological treatment and tapering/discontinuation.
- Preauthorization requirements for certain medications prescribed in a “*chronic phase*”

“**Companion Guide**” — Provides guidance as to how the Commission expects the rules to be implemented

New Ex Parte Communication Forms – released with the “Companion Guide”

Important Terminology

“Acute Phase” – Treatment within 12 weeks of:

- a compensable injury,
 - an aggravation of a compensable injury, or
 - a surgery for a compensable injury
- (Note that there can be multiple “*acute phases*” in the same claim.)

“Chronic Phase” – Treatment more than 12 weeks from the beginning of the last “*acute phase*.”

Transition to Compliance with the Rules

- No “legacy claims” or “legacy period.” (Claims that aren’t affected by the rules will never be affected by the rules).
- For affected claims, Companion Guide recommends a transition period of up to 6 months.

{{cta('7afd087a-7157-46b8-9b2d-fe86f8c72696','justifycenter')}}}



©2022 Enlyte Group, LLC.

mitchell | genex | coventry